1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Array Celebrates BEACON Of Hope For Anti-BRAF/MEK/EGFR Triplet In Colorectal Cancer

 
• By Eleanor Malone

New data on Array BioPharma's encorafenib and binimetinib together with cetuximab add hopes for its future in colorectal cancer. Recent strong data in melanoma for the BRAF/MEK combo are expected to be followed by its first US approval in the coming days.

a beautiful beacon appears on a foggy day
Beacon of hope for Array in CRC

Overall survival data from Array BioPharma Inc.'s Phase III BEACON CRC safety lead-in trial of its BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and Eli Lilly & Co./Merck KGaA's anti-EGFR antibody Erbitux (cetuximab) suggest the triplet combination could prove valuable as a treatment for BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Array reported at the European Society of Medical Oncology's gastrointestinal cancer conference (ESMO-GI) in Barcelona June 23 that the combo...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

More from Therapy Areas

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.